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Background: Substance abuse and gambling problems are associated, however, studies on gambling problems
among opioid substitution treatment (OST) patients are scarce. The aims of this study are to explore the association
of gender, age, treatment medication and treatment program with gambling behaviour, including gambling
participation and gambling problems, among OST patients.
Findings: All OST patients (n = 244) in three Finnish outpatient clinics were recruited in March − April 2014. The
response rate was 64.3%. OST programs included two choices of orientation (rehabilitative/harm reduction) and
two choices for treatment medication (methadone/buprenorphine-naloxone). Of 144 respondents, 70.1% had
gambled during the past year and 12.5% were identified as potential past-year problem gamblers. Gambling was
statistically significant more commonly among males (79.8%) compared with females (53.7%). Similarly patients in
the rehabilitative program gambled (75.9%) more than those in the harm reduction program (50.0%). Gender, age,
treatment medication or treatment program was not associated with past-year gambling problems.
Conclusions: Gambling participation of the OST patients seemed to be somewhat similar compared with the
Finnish general population, but gambling problems were more common among OST patients. Gender and age
may not be very strong indicators of risk while screening problem gamblers among OST patients. Institution of a
problem gambling screening program is recommended, and additional intervention for gambling problems should
be implemented for that need as a part of OST.
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Opioid addiction, as in other addictions, is characterized
by behaviours including one or more of the following
manifestations related to drug use: impaired control,
compulsive use, craving and continued use regardless of
harm [1]. These diagnostic manifestations resemble those
of gambling disorder (GD) as categorized by the DSM-5
[1]. Both substance use disorder (SUD) and GD present a
loss of control over a person’s behaviour and also have
negative personal, vocational and social consequences.
The prevalence of opioid abuse worldwide is 0.4% [2]
while the standardized problem gambling prevalence
rate varies from 0.5% to 7.6% [3]. Among misusers, how-
ever, the prevalence of GD is considerably higher varying
from 8% to 21% and even higher (17% to 27%) among* Correspondence: kaarlo.simojoki@a-klinikka.fi
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unless otherwise stated.patients in methadone maintenance treatment (MMT)
[4,5]. Based on both population studies and studies from
the clinical context, males and people younger than
35 years gamble more and have more gambling problems
than females or people 35 years or older [6-8]. Charac-
teristically, patients with opioid dependence also have
other comorbidities: typically either problems with
other substances or co-occurring psychiatric disorders
such as depression or anxiety and personality disorders
[9-11]. Similarly, patients with GD seem to have a high rate
of co-occurring SUD and psychiatric disorders [4,12,13].
Based on previous studies, both GD and SUD may be
present as a primary addiction: GD may precede SUD or
vice versa [14,15]. However, only a few studies have
addressed the issue of a concomitant GD within SUD
patients such as patients within opioid substitution treat-
ment (OST) [5,15,16].
In Finland, the rehabilitation oriented OST focuses on
abstinence and psychosocial rehabilitation using structured. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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on the patient’s quality of life and consists of services pro-
moting safer use of drugs and injection facilities, overdose
prevention, social and health issues, and peer support.
The harm reduction approach is used with patients who
are currently not able to quit drug use. The patients are
selected to the different programs according to the sever-
ity of addiction, psychiatric comorbidities and assumed
capability of rehabilitation. Methadone is the choice for
more severe patients, who have to attend the clinic daily.
In both of the orientations, the choice of treatment medi-
cation (methadone/buprenorphine-naloxone) is based on
an individual assessment and tailored to the needs of each
patient [17].
In order to better treat the patients with dual diagnosis
of both opioid addiction and GD, more research is
needed to understand how these disorders are related
and how the concomitant presence of these disorders
possibly affect their treatment. The aims of this study
are to explore the association of gender, age, treatment
medication and treatment program with gambling be-
haviour, including gambling participation and gambling
problems, among OST patients.
Methods
Cross–sectional data (n = 144) was based on a total sam-
ple of 224 OST patients treated between March and April
2014 at three outpatient clinics in Finland. The response
rate of the study was 64.3%. The data regarding gambling
behaviour were collected as a part of clinical work
and used in this study with the approval of the Ethical
Committee of the A-Clinic Foundation.
Past-year gambling participation was inquired using a
question: “Have you gambled during the past 12 months?”
with yes/no answers. Past-year gambling problems were
assessed using the Brief Biosocial Gambling Screen (BBGS)
[18], a three-item scale measuring neuro-adaptation, psy-
chosocial characteristics and adverse social consequences
of gambling (Table 1) with Cronbach Alpha of 0.70.
In the instructions gambling was defined as follows:Table 1 The proportion of endorsed criteria for problem gam
outpatient clinics
Criteria Question
1. Neuro-adaptation: “During the past 12 month
when trying to stop/cut d
2. Psychosocial characteristics “During the past 12 month
knowing how much you g
3. Adverse social consequences of gambling “During the past 12 month
gambling that you had to
Past-year gambling problems*
BBGS, Brief Biosocial Gambling Screen; The response options included yes and no. *On
gambling problems.“Gambling means games you can play with money, for ex-
ample, lotteries, Keno, slot machine games, internet gam-
bling (e.g. internet poker) and horse trotting games.”
Independent variables included gender, age, orientation
of the treatment program (rehabilitative/harm reduction)
and the type of treatment medication (methadone/bupre-
norphine-naloxone).
Two formulations of sublingual tablets of buprenorphine:
mono-buprenorphine (Subutex®), supplied as 0.4 mg, 2 mg
and 8 mg tablets and buprenorphine-naloxone (Suboxone®),
supplied as 2 mg (buprenorphine)/0.5 mg (naloxone) and
8 mg (buprenorphine)/2 mg (naloxone). Administration of
the medication in the harm reduction group was supervised
5–7 times per week and in the rehabilitative group at least
once a week, depending on the patient’s individual treat-
ment plan. Treatment retention among OST patients in
Finland is up to 80% after 18-month follow-up [19,20].
The data were analysed using SPSS 21.0 software
(SPSS, Inc., Chicago, IL, USA). Statistical significance (p)
was determined using the Fisher’s exact test. The Odds
Ratio (OR) was calculated separately for each variable.
Findings
A total of 144 patients (62.2% males) participated in this
study (Table 2). The mean age for males was 36.6 (SD 7.0,
range 22–55) and for females 34.7 (SD 9.0, range 22–59).
The patients in the rehabilitative program were younger
than the patients in the harm reduction program.
77.8% participated in the rehabilitative treatment
program while 22.2% participated in the harm reduc-
tion program. 49.3% used methadone and 50.7% used
buprenorphine-naloxone as the treatment medication
(Table 2).
70.1% had gambled during the past year. Past-year
gambling was more common among males (79.8%) com-
pared with females (53.7%, p < 0.001, OR 3.40) (Table 3).
Past-year gambling was more common among patients
in the rehabilitative program (75.9%) compared with pa-
tients in the harm reduction program (50.0%, p = 0.008).
The OR of being a gambler in the rehabilitative programbling among the patients (n = 144) treated at the
n (%)
s, have you become restless, irritable or anxious
own on gambling?”
13 (9.0)
s, have you tried to keep your family or friends from
ambled?”
7 (4.9)
s did you have such financial trouble as a result of your
get help with living expenses from family, friends or welfare?”
8 (5.6)
18 (12.5)
e or more positive answers (yes) to the questions indicated potential past-year









Males 89 (62.2) 72 (80.9) 17 (19.1)
Females 54 (37.8) 40 (74.1) 14 (25.9)
Age
≤24 years 6 (4.2) 6 (100.0) -
25-34 years 64 (44.4) 56 (87.5) 8 (12.5)
35-44 years 54 (37.5) 39 (72.2) 15 (27.8)
≥45 years 20 (13.9) 11 (55.0) 9 (45.0)
Treatment medication
Methadone 71 (49.3) 47 (66.2) 24 (33.8)
Buprenorphine-
naloxone
73 (50.7) 65 (89.0) 8 (11.0)
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in past-year gambling between the two age groups.
Based on the BBGS, 12.5% of the respondents had
scores indicating potential gambling problems (Table 1).
The criteria measuring neuro-adaptation was endorsedTable 3 Association between the correlates and past-year







Gender p < 0.001
Males 71 (79.8) 18 (20.2) 3.40
Females 29 (53.7) 25 (46.3) a
Age p = 0.368
<35 years 52 (74.3) 18 (25.7) 1.47




Methadone 46 (64.8) 25 (35.2) 1.66
Buprenorphine-
naloxone
55 (75.3) 18 (24.7) a
Treatment program p = 0.008
Rehabilitative 85 (75.9) 27 (24.1) 3.15














16 (50.0) 16 (50.0) a
Significance is determined by Fischer’s exact test; Odds Ratio is calculated
separately for each variable; a, reference group.most commonly (9.0%), while 4.9% endorsed the criteria
measuring psychosocial characteristics and 5.6% en-
dorsed adverse social consequences of gambling.
There were more males with gambling problems
(14.8%) than females (11.2%) (Table 4). There were also
more 35 years or older patients (13.5%) with gambling
problems than younger than 35 years (11.4%). Respon-
dents in the rehabilitative program (14.3%) had more
gambling problems than those in the harm reduction
program (6.2%). Gambling problems were more com-
mon among those using methadone (15.5%) than those
using buprenorphine-naloxone (9.6%). 21.3% of the re-
spondents in the rehabilitative program using metha-
done had gambling problems (OR 4.05), which was
higher than in other treatment combinations. None of
these differences were statistically significant.
Discussion
The proportion of past-year gamblers among OST pa-
tients was at a slightly lower level than in the Finnish
general population sample. However, the past-year
prevalence of gambling problems among OST patients
was clearly higher (12.5%) than at the population level
(2.7%) [21], being in line with previous studies [5,14,16].
Yet, it is important to notice that previous studies
assessed severity of gambling using a different instru-
ment and time frame to this study. Weinstock and col-
leagues [16] used a self-report survey with the South
Oaks Gambling Screen (SOGS) of both lifetime and past
two months time frame. Peles and colleagues [5] used
SOGS as a lifetime measure, whereas Ledgerwood and
Downey [16] altered SOGS to assess the past three
months severity of gambling. Time frame, in particular,
is an important factor while comparing different studies,
since the lifetime measure of gambling is not sensitive to
current gambling problems due to false positive answers
[22], whereas the past two and three months are specif-
ically addressing the current situation. We used BBGS,
which has good psychometric properties [18]. An instru-
ment with a 12-month time frame was selected to ex-
clude the participants in sustained remission of GD [1].
Adding another measure alongside the BBGS would be
worth considering in the future.
Neuro-adaptation was the most endorsed criterion in
the BBGS. This criterion refers to the behavioural mani-
festations of withdrawal – irritability and anxiety upon
cessation of gambling. This can reflect the known simi-
larities of SUD and GD [23,24]. The endorsement of this
particular criterion may also reflect the characteristics of
this particular population, where symptoms of with-
drawal may overlap another addiction.
Our results confirmed that male patients in OST gam-
ble significantly more than female patients [5]. However,
this particular gender difference was not statistically
Table 4 Association between the correlates and past-year gambling problems among patients treated at the outpatient
clinics
Gambling problem* n (%) No gambling problems n (%) Significance Odds ratio
Gender p = 0.606
Males 8 (14.8) 79 (85.2) 1.37
Females 10 (11.2) 46 (88.8) a
Age p = 0.803
<35 years 8 (11.4) 62 (88.6) a
≥35 years 10 (13.5) 64 (86.5) 1.21
Treatment medication p = 0.322
Methadone 11 (15.5) 60 (84.5) 1.73
Buprenorphine-naloxone 7 (9.6) 66 (90.4) a
Treatment program p = 0.363
Rehabilitative 16 (14.3) 96 (85.7) 2.50
Harm reduction 2 (6.2) 30 (93.8) a
Treatment combination p = 0.112
Rehabilitative with methadone 10 (21.3) 37 (78.7) 4.05
Rehabilitative with buprenorphine-naloxone 6 (9.2) 59 (90.8) 1.53
Harm reduction with either medication 2 (6.2) 30 (93.8) a
The data (n = 144); *BBGS = 1+, Brief Biosocial Gambling Screen: one or more positive answers (yes) indicated potential past-year gambling problems; Significance
is determined by Fischer’s exact test; Odds Ratio is calculated separately for each variable; a, reference group.
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be less associated with GD than at the population level
and is not necessarily a moderator of gambling behaviour
as compared to, for example, chemical addictions [7].
Patients in OST did not differ from the general Finnish
population regarding participation in gambling activities
[21]. Patients who were younger than 35 years gambled
more often than the 35 years or older patients. However,
the proportion of 35 years or older patients categorized as
probable problem gamblers was higher than that of the
younger ones. Even though these differences did not attain
statistical significance this may reflect the characteristics
of the patients in OST in general, them being somewhat
over 30 years old [5], which in turn differ with the findings
among the general population [21].
The patients in the rehabilitation oriented program
gambled significantly more and had more gambling
problems than the patients in the harm reduction pro-
gram. Could the patients in the rehabilitative program,
with the goal of eventually quitting all drug use, and
consequently having less euphoric experience due to
treatment, be chasing the euphoria by gambling? SUD
and GD co-occur commonly and may manifest either on
a behavioural level (for example, behavioural addiction
may be fuelled by substance use) or on a syndromal level
(for example, a behavioural addiction starts after SUD
treatment) [24].
Understanding the similarities, as well as the inter-
action between GD and SUD, is important in developing
treatments especially for these two addictions occurringsimultaneously. It can be hypothesised that the patients
attending the rehabilitative program may have an in-
creased risk to develop a behavioural addiction (i.e. GD),
as a replacement of the opioid addiction. As some studies
[25-28] suggest, there may be a behavioural interaction
between GD and SUD. On the other hand, it may be ex-
plained by the theory of a common liability to addiction
[29]. In both GD and SUD reduced control over strong
behaviour and urge for immediate rewards [30] have been
identified. Conversely, the patients in the harm reduction
program may have limited interest in gambling activities,
as well as capabilities (e.g. economic, social and cognitive)
in other activities due to the severity of their primary
diagnosis.
Buprenorphine-naloxone was used more often than
methadone, especially among the patients attending the
rehabilitative program. Patients in a rehabilitative pro-
gram with buprenorphine-naloxone had less gambling
problems compared to those in a rehabilitative program
with methadone. In turn, the patients receiving metha-
done seem to have more gambling problems. Thus, could
buprenorphine-naloxone formulation Suboxone® have an
effect in decreasing gambling urges [31,32], since it con-
tains 10% of naloxone [33]?
This study is limited by the small sample size, the limited
number of background variables (e.g. socio-demographic
characteristics, type of gambling, comorbid conditions)
and the bivariate analysis. In addition, parallel use of other
psychoactive drugs, which may be associated with prob-
lematic gambling was not recorded here, thus future
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largely unexplored. The data are unique and represent
well the patients treated in the outpatient clinics. The
number of patients, including the amount of females, who
attended the treatment, represents around 5% of the total
number of OST patients in Finland. Their background is
also representative, thus not reported here. The clinics
represent two different major treatment programs used in
Finland [19,20]. However, some of our results did not reach
statistical significance, thus a power analysis is recom-
mended in future studies. Gambling problems were mea-
sured using a translated and back-translated Finnish
version of the BBGS [18], which has not yet been validated
in the Finnish or OST context. This study mainly offers va-
luable suggestive information to clinical practice, includes
two relevant lines of treatment approaches (those based on
opioid withdrawal and those based on agonist mainten-
ance) [34] and recommendations for further research.
Conclusions
Gambling participation of the patients in OST seems to
be somewhat similar compared with the Finnish general
population, but gambling problems were more common
among the patients in OST. The gender and age may
not be very strong indicators of risk among patients in
OST. Assessment of possible gambling problems should
be included in clinical practice, and additional interven-
tion in gambling problems should be implemented for
those in need as a part of OST. A comprehensive system
of screening, brief intervention and treatment referral as
a part of a public health approach, for example similar
to SBIRT (http://www.samhsa.gov/sbirt), should also be
implemented for behavioural addictions occurring alone
or with substance use disorders. It has already been
noted [14] that OST patients who have concomitant
gambling problems may benefit from additional support.
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